A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies

NCT01805375 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Indolent B-cell Lymphoma
Chronic Lymphocytic Leukaemia
Waldenström Macroglobulinaemia

Interventions

DRUG: DI-B4

Sponsor

Cancer Research UK